← Back to Clinical Trials
Recruiting NCT05936346

Evaluation of Safety and Tolerability of Salvia Haenkei Extract As a Dietary Supplement Ingredient

Trial Parameters

Condition Aging
Sponsor IBSA Farmaceutici Italia Srl
Study Type INTERVENTIONAL
Phase N/A
Enrollment 50
Sex ALL
Min Age 55 Years
Max Age 65 Years
Start Date 2023-07-17
Completion 2025-04-30
Interventions
Salvia haenkei 175mgSalvia haenkei 350mg

Brief Summary

Evalution of the safety and tolerability of the oral administration of Salvia haenkei in a healthy population.

Eligibility Criteria

Inclusion Criteria: * Informed consent as documented by signature * Male or female * Age 55-65 years, inclusive * In good general health as evidenced by medical history and current health status * Willingness to maintain dietary and sports habits as of baseline * Willingness and ability to comply with the requirements of the study Exclusion Criteria: * Body Mass Index \< 18.5 or ≥ 30 * Difficulty in swallowing (dysphagia) * Known allergy or sensitivity to any ingredient of the study intervention * Any medical condition or clinically significant abnormalities in laboratory values (hematology, blood chemistry, urinalysis) at screening which in the judgment of the Investigator makes the subject unsuitable for the study * Planned or anticipated major surgical procedure during the subject's participation in this study * Inability or contraindications to undergo the study intervention * Inability to follow the procedures of the study (e.g. due to language problems, psychological disorders, d

Related Trials